F A Shepherd

Summary

Affiliation: St. Michael's Hospital
Country: Canada

Publications

  1. ncbi request reprint Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study
    F A Shepherd
    Department of Medicine of the Toronto Hospital, Canada
    J Clin Oncol 16:1736-42. 1998
  2. ncbi request reprint Treatment of Kaposi's sarcoma after solid organ transplantation
    F A Shepherd
    Department of Medicine, The Multi Organ Transplant Program of The Toronto Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 15:2371-7. 1997
  3. ncbi request reprint Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer
    F A Shepherd
    Toronto Hospital, Ontario, Canada
    Lung Cancer 17:S121-36. 1997
  4. ncbi request reprint Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
  5. doi request reprint Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer
    Geoffrey Liu
    Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Canada
    J Thorac Oncol 7:316-22. 2012
  6. ncbi request reprint Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
    N Murray
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 17:2300-8. 1999
  7. pmc Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study
    F A Shepherd
    Interdepartmental Division of Oncology of the University of Toronto, Ontario, Canada
    Br J Cancer 78:683-5. 1998
  8. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
  9. doi request reprint Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    R Goodwin
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Ann Oncol 21:2220-6. 2010
  10. ncbi request reprint Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials
    F A Shepherd
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Semin Oncol 28:4-9. 2001

Detail Information

Publications40

  1. ncbi request reprint Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study
    F A Shepherd
    Department of Medicine of the Toronto Hospital, Canada
    J Clin Oncol 16:1736-42. 1998
    ..These observations led to our trial of zidovudine with two dose levels of interferon alfa...
  2. ncbi request reprint Treatment of Kaposi's sarcoma after solid organ transplantation
    F A Shepherd
    Department of Medicine, The Multi Organ Transplant Program of The Toronto Hospital, University of Toronto, Ontario, Canada
    J Clin Oncol 15:2371-7. 1997
    ....
  3. ncbi request reprint Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer
    F A Shepherd
    Toronto Hospital, Ontario, Canada
    Lung Cancer 17:S121-36. 1997
    ..It remains only speculative at this time as to whether manipulation of abnormal genes in malignant cells will be clinically possible, and whether treatment of this sort may be applied in an adjuvant setting...
  4. ncbi request reprint Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    F A Shepherd
    University of Toronto, Toronto, and London Regional Cancer Centre, London, Ontario, Canada
    J Clin Oncol 18:2095-103. 2000
    ..Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life...
  5. doi request reprint Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer
    Geoffrey Liu
    Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Canada
    J Thorac Oncol 7:316-22. 2012
    ..Predictive and prognostic analyses of epidermal growth factor receptor (EGFR), ABCG2, and AKT1 genetic polymorphisms were performed...
  6. ncbi request reprint Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
    N Murray
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 17:2300-8. 1999
    ..To determine whether an intensive weekly chemotherapy regimen plus thoracic irradiation is superior to standard chemotherapy in the treatment of extensive-stage small-cell lung cancer (ESCLC)...
  7. pmc Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study
    F A Shepherd
    Interdepartmental Division of Oncology of the University of Toronto, Ontario, Canada
    Br J Cancer 78:683-5. 1998
    ..5% of patients. Median survival times were 16.2 and 18.7 months for radiotherapy alone and chemotherapy-surgery respectively (P = Ns), with no long-term improvement in survival seen with combined-modality treatment...
  8. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
    ..To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin...
  9. doi request reprint Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24
    R Goodwin
    NCIC Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    Ann Oncol 21:2220-6. 2010
    ....
  10. ncbi request reprint Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials
    F A Shepherd
    Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Semin Oncol 28:4-9. 2001
    ..The adverse events observed were predictable, tolerable, and manageable. These phase III trials showed that docetaxel provided clinical benefits to patients with non-small cell lung cancer...
  11. ncbi request reprint Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness
    P A Bradbury
    Princess Margaret Hospital, Toronto, ON, Canada Queen s University NCIC Clinical Trials Group, Kingston, ON, Canada Sunnybrook Health Sciences Centre, Toronto, ON, Canada Juravinski Cancer Centre, Hamilton, ON, Canada
    J Clin Oncol 26:6531. 2008
    ..21 trial of erlotinib versus placebo in advanced NSCLC. Here, we investigate the value of combining clinical and molecular predictors of outcome to identify more, and less cost- effective patient subgroups for treatment...
  12. doi request reprint An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    A M Horgan
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Ann Oncol 22:1805-11. 2011
    ..Gefitinib had a better toxicity profile and greater improvements in quality of life (QoL). We undertook a cost-consequence analysis to estimate the direct medical costs of gefitinib compared with docetaxel...
  13. ncbi request reprint Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group
    F A Shepherd
    The Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, 5 104, Toronto, Ontario, M5G 2M9, Canada
    Cancer 92:595-600. 2001
    ..This study was undertaken to determine the response to pemetrexed disodium given in combination with cisplatin...
  14. doi request reprint The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials
    P Wheatley-Price
    Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    Ann Oncol 21:2023-8. 2010
    ..We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy...
  15. ncbi request reprint Validity of sexual histories in a prospective study of male sexual contacts of men with AIDS or an AIDS-related condition
    R A Coates
    Department of Preventive Medicine and Biostatistics, Faculty of Medicine, University of Toronto, Ontario, Canada
    Am J Epidemiol 128:719-28. 1988
    ..However, some caution may be necessary in interpreting the results for some activities (anal digit insertion, anilingus) since agreement is less satisfactory for these activities...
  16. ncbi request reprint Angiogenic factors and soluble receptors in NCIC CTG BR.24
    C L Addison
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada NCIC Clinical Trials Group, Kingston, ON, Canada Ottawa Hospital Research Institute, Ottawa, ON, Canada Ottawa Hospital Cancer Centre, Ottawa, ON, Canada The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada NCIC Clinical Trials Group, Queen s University, Kingston, ON, Canada Queen s University, Kingston, ON, Canada
    J Clin Oncol 29:3047. 2011
    ..CED improved response and progression free survival (PFS). We examined potential predictive or prognostic biomarkers...
  17. ncbi request reprint A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the NCIC CTG JBR.10 trial
    R W Jang
    Princess Margaret Hospital, Toronto, ON, Canada National Cancer Institute of Canada, Kingston, ON, Canada University of Alberta, Edmonton, AB, Canada
    J Clin Oncol 26:6535. 2008
    ..To aid in treatment decision-making, quality-adjusted survival estimates of the JRB.10 trial were derived using a Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) analysis...
  18. ncbi request reprint Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group
    A Le Maitre
    National Cancer Institute of Canada, Kingston, ON, Canada National Cancer Institute of Canada, Kingston, ON, Canada University Health Network, Princess Margaret Hospital, Toronto, ON, Canada Margaret and Charles Juravinski Cancer Centre, Hamilton, ON, Canada
    J Clin Oncol 26:8065. 2008
    ..Using data from three lung cancer trials conducted by NCIC CTG we analyzed bleeding in participating patients using LMWH, C or non-steroidal anti-inflammatories (NSAID)...
  19. ncbi request reprint The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer (NSCLC) chemotherapy trials
    P Wheatley-Price
    Princess Margaret Hospital, Toronto, ON, Canada Queen s University, Kingston, ON, Canada McGill University, Montreal, QC, Canada
    J Clin Oncol 26:8054. 2008
    ..Increased chemotherapy (CT) toxicity has been reported in women with small cell lung-cancer. We investigated the influence of sex on efficacy, toxicity, quality of life (QoL) and dose-delivery in NSCLC...
  20. ncbi request reprint The impact of brain metastases on overall survival (OS) in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) clinical trials (CT) in advanced non-small cell lung cancer (NSCLC)
    P A Bradbury
    NCIC CTG, Queen s University, Kingston, ON, Canada Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
    J Clin Oncol 27:8075. 2009
    ..We evaluated the validity of this exclusion criterion, by investigating the OS of stage IV NSCLC pts with (BMet) and without (non-BMet) a prior history of BMet recruited to NCIC CTG CTs...
  21. ncbi request reprint Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer
    F A Shepherd
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario
    Semin Oncol 28:30-7. 2001
    ..Miscellaneous treatments, including monoclonal antibody therapy, tamoxifen, and growth factor inhibition have not yet been shown to have a role in the treatment of SCLC. Semin Oncol 28 (suppl 4):30-37...
  22. ncbi request reprint Angiogenesis inhibitors in the treatment of lung cancer
    F A Shepherd
    Division of Medical Oncology, Department of Medicine, Princess Margaret Hospital, 610 University Avenue, 5 104, University of Toronto, Ont, Toronto, Canada, M5G 2M9
    Lung Cancer 34:S81-9. 2001
    ..Numerous other anti-angiogenesis agents are in early clinical trials, but have not been evaluated in lung cancer yet...
  23. ncbi request reprint Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small cell lung cancer
    A M Horgan
    Princess Margaret Hospital, Toronto, ON, Canada
    J Clin Oncol 26:8110. 2008
    ..8110 Background: The INTEREST trial is the first to demonstrate non-inferiority of EGFR TKI gefitinib compared to standard second-line chemotherapy (docetaxel) in NSCLC,with better quality of life in gefitinib-treated patients...
  24. ncbi request reprint Economic issues in lung cancer: a review
    P J Goodwin
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 16:3900-12. 1998
    ..It is estimated that lung cancer is responsible for 20% of all cancer care costs. Concerns exist that this expenditure is associated with questionable benefits...
  25. ncbi request reprint Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin
    D J Stewart
    Division of Medical Oncology, Ottawa Regional Cancer Centre, Ontario, Canada
    J Clin Oncol 15:1897-905. 1997
    ....
  26. ncbi request reprint A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients
    M S Tsao
    Princess Margaret Hospital, Toronto, ON, Canada Ontario Cancer Institute, Toronto, ON, Canada Queen s University, Kingston, ON, Canada Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 26:7510. 2008
    ..Gene expression profiling may identify patient groups with significantly different prognosis, with potential for improved selection of patients to receive adjuvant chemotherapy...
  27. ncbi request reprint An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib
    J F Hilton
    NCIC Clinical Trials Group, Kingston, ON, Canada Queen s University, Kingston, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada NCIC Clinical Trials Group, Queen s University, Kingston, ON, Canada
    J Clin Oncol 29:7523. 2011
    ..Gastric acid suppression (AS), through the use of proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RA), increases gastric pH which may reduce the absorption of E...
  28. ncbi request reprint A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19
    G D Goss
    The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada The Ottawa Hospital Research Institute, Ottawa, ON, Canada University Health Network, Princess Margaret Hospital, Toronto, ON, Canada NCIC Clinical Trials Group, Kingston, ON, Canada Medical Oncology Hematology Consultants, PA, Newark, DE University of California, Davis, Sacramento, CA Naval Medical Center, Portsmouth, Portsmouth, VA Medical Oncology, Mayo Clinic, Rochester, MN University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    J Clin Oncol 28:LBA7005. 2010
    ..Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, showed activity in monotherapy trials. We report a trial of adj gefitinib versus placebo after complete resection of NSCLC...
  29. ncbi request reprint A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC)
    A M Brade
    Princess Margaret Hospital, Toronto, ON, Canada Ottawa Regioanl Cancer Centre, Ottawa, ON, Canada Eli Lilly Canada, Scarborough, ON, Canada
    J Clin Oncol 26:7550. 2008
    ..Pemetrexed/Cisplatin (PC) has shown activity in the stage IV setting and full dose P plus RT or RT/carboplatin appears tolerable...
  30. pmc Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
    T Reiman
    Department of Medicine, Dalhousie University and Department of Oncology, Saint John Regional Hospital, Saint John, NB, Canada
    Ann Oncol 23:86-93. 2012
    ..We explored this further in additional patients from JBR.10 and the other three trials...
  31. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008
    ..The DA for advanced NSCLC is feasible, acceptable to patients and improves understanding of advanced NSCLC without increasing patient anxiety...
  32. doi request reprint The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
    P Wheatley-Price
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario
    Ann Oncol 21:232-7. 2010
    ..Previous studies reported that women survive longer than men, but experience greater toxicity, when treated for small-cell lung cancer (SCLC)...
  33. ncbi request reprint Factors influencing a specific histologic diagnosis of non-small cell lung cancer
    J A Sulpher
    Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Department of Medicine, University of Ottawa, Ottawa, ON, Canada Medical Oncology and Hematology Division, Department of Medicine, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada Princess Margaret Hospital, Toronto, ON, Canada Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    J Clin Oncol 29:7541. 2011
    ..Increasingly specific classification of NSCLC is required to select optimum therapy. We performed a multi-centre retrospective review of NSCLC cases to identify factors associated with a specific histological diagnosis...
  34. ncbi request reprint Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC)
    D R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN The London Clinic, London, United Kingdom Sarah Cannon Research Institute, Nashville, TN San Camillo Forlanini Hospital, Rome, Italy David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA University of Texas M D Anderson Cancer Center, Houston, TX Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT Catalan Institute of Oncology, Barcelona, Spain Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Spain Princess Margaret Hospital, Toronto, ON, Canada University of North Carolina at Chapel Hill, Chapel Hill, NC Cluzeau Hospital, Limoges, France
    J Clin Oncol 29:TPS220. 2011
    ..This phase III study will compare the results of treatment with the gemcitabine/carboplatin doublet alone or in combination with iniparib. The primary endpoint is overall survival...
  35. pmc Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer
    C Q Zhu
    Division of Applied Molecular Oncology, Ontario Cancer Institute, Ontario, Toronto, Canada
    Br J Cancer 94:1452-9. 2006
    ..16, P=0.03). These data indicate that gene amplification is an important mechanism for hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker for disease-free survival in NSCLC...
  36. ncbi request reprint Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006
    ..Response rates for second-line chemotherapy are 15-25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC...
  37. ncbi request reprint Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors
    D Soulieres
    Centre Hospitalier de l Universite de Montreal, Montreal, QC, Canada Novella Clinical, Boulder, CO Princess Margaret Hospital, Toronto, ON, Canada Ospedale Civile di Livorno, Livorno, Italy University of Colorado Denver Cancer Center, Aurora, CO University of Texas M D Anderson Cancer Center, Houston, TX University of Colorado Denver, Aurora, CO Aberdeen Royal Infirmary, Aberdeen, United Kingdom Aichi Cancer Center Hospital, Nagoya, Japan University Health Network, Princess Margaret Hospital, and University of Toronto, Toronto, ON, Canada National Taiwan University, Taipei, Taiwan OSI Pharmaceuticals, Boulder, CO F Hoffmann La Roche, Basel, Switzerland OSI Pharmaceuticals, Farmingdale, NY University of California, Davis Cancer Center, Sacramento, CA
    J Clin Oncol 29:7533. 2011
    ....
  38. pmc Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk
    G Liu
    Department of Medicine, Division of Medical Oncology and Hematology, Ontario Cancer Institute, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Oncogene 30:3295-304. 2011
    ..These polymorphisms thus have the potential to identify a sub-population of smokers at greater lung cancer risk, wherein this risk could be driven by an aberrant SWI/SNF chromatin-remodeling pathway...
  39. ncbi request reprint Cancer incidence among Canadian kidney transplant recipients
    P J Villeneuve
    Department of Public Health Sciences, University of Toronto, Toronto, ON, Canada
    Am J Transplant 7:941-8. 2007
    ..Our findings underscore the need for increased vigilance among kidney transplant recipients for cancers at sites where there are no population-based screening programs in place...
  40. ncbi request reprint Comparison of three HIV antigen detection kits in sequential sera from a cohort of homosexual men
    S E Read
    Department of Pediatrics, Faculty of Medicine, University of Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 4:717-23. 1991
    ..There are significant differences in the performance characteristics of these commercial products for the detection of HIV antigen in serum...